QR Code

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

Pijian Yang1,*, Yuzhen Liang2,*, Yunchen Luo,2 Zhengming Li,2 Yumei Wen,1 Jing Shen,1 Ruwen Li,1 Hua Zheng,3 Harvest F Gu4,*, Ning Xia1,*1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, People’s Republic of China; 2Depart...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Yang P, Liang Y, Luo Y, Li Z, Wen Y, Shen J, Li R, Zheng H, Gu HF, Xia N
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Dove Medical Press 2019-07-01
Rangatū:Diabetes, Metabolic Syndrome and Obesity
Ngā marau:
Glucagon like peptide 1
Liraglutide
Nonalcoholic fatty liver disease
Insulin resistance
Insulin signaling
Urunga tuihono:https://www.dovepress.com/liraglutide-ameliorates-nonalcoholic-fatty-liver-disease-in-diabetic-m-peer-reviewed-article-DMSO
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite